Introduction This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.
BioSeeker has in this very insightful publication focused on Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five included big pharma companies. The collective force of the above research and analysis ’decodes’ these five big pharma R&D efforts into strategy revealing and gap filing presentations. Enough to fuel and sustain comparative benchmarking, peer group surveillance, and partnership decisions. Decoding Big Pharma’s R&D Strategy in Oncology in numbers: - Includes references to more than 250 drugs and 600 clinical/preclinical trials
- Addresses the competitive situation on more than 80 different cancer indications, including supportive care indications
- Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase inhibitor- and Vaccine drugs for the treatment of cancer
- The included competitive landscape between the five big pharma includes more than 200 companies related to cancer drug development
- Last five years of deals and alliances in oncology, including almost a hundred different key deals and alliances
- Target analysis of 119 drug targets in oncology, including molecular function of target, target localization, type of compound for targeting, targets affecting signaling pathways etc
- Drug compound analysis by cancer indications
Pages: 243 Table of Contents Download TOC in PDF
|
